Notably, this construct effectively overcomes CD19-mediated immune escape, exhibiting efficacy against heterogeneous leukemia that is superior to that blinatumomab, while also addressing the design limitations of natural ligands and outperforming conventional BAFF CAR-T cells in lymphoma treatment. The gene discussed is CD19; the disease is lymphoma.